• menu

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
    Pembrolizumab
    |
    Weekly News Recap #Phispers Pembrolizumab
    Lilly buys three vaccine drugmakers in deals worth up to US$ 3.8 bn; FDA approves AbbVie’s ultra rare blood cancer drug

    Lilly buys three vaccine drugmakers in deals worth up to US$ 3.8 bn; FDA approves AbbVie’s ultra rare blood cancer drug

    Buoyed by the rising sales of its obesity drug, Eli Lilly has been on an acquisition spree this year. The company announced ag...

    Impressions : 1517

    FDA issues warning letter to Chinese supplier of semaglutide; approves AstraZeneca’s new treatment for hypertension

    FDA issues warning letter to Chinese supplier of semaglutide; approves AstraZeneca’s new treatment for hypertension

    In Phispers this week, the US Food and Drug Administration (FDA) approved AstraZeneca’s first-in-class treatment for hype...

    Impressions : 2264

    FDA seeks more safety data from Lilly on obesity drug Foundayo; Novo partners OpenAI to speed up drug development

    FDA seeks more safety data from Lilly on obesity drug Foundayo; Novo partners OpenAI to speed up drug development

    This week’s Phispers brings you news on how artificial intelligence (AI) is taking centerstage in the world of pharmaceut...

    Impressions : 2336

    Merck buys Terns Pharma for US$ 6.7 bn to boost cancer portfolio; Novartis acquires Synnovation unit for up to US$ 3bn

    Merck buys Terns Pharma for US$ 6.7 bn to boost cancer portfolio; Novartis acquires Synnovation unit for up to US$ 3bn

    This week’s Phispers is packed with news of drug approvals and M&As. Merck is preparing for its future post-Keytruda pate...

    Impressions : 1012

    FDA approves J&J’s plaque psoriasis pill; federal judge blocks key parts of RFK Jr’s childhood vaccine policy overhaul

    FDA approves J&J’s plaque psoriasis pill; federal judge blocks key parts of RFK Jr’s childhood vaccine policy overhaul

    As the war in the Middle East intensifies, the world is facing disruption of major air and sea routes. The war is already disr...

    Impressions : 1264

    Moderna resolves vaccine patent dispute with Roivant, Arbutus; FDA grants accelerated approval to Ascendis’ dwarfism therapy

    Moderna resolves vaccine patent dispute with Roivant, Arbutus; FDA grants accelerated approval to Ascendis’ dwarfism therapy

    Over the past week, tensions in the Middle East have escalated sharply after the US and Israel launched military strikes on Ira...

    Impressions : 1019

    FDA refuses to review Moderna’s mRNA-based flu vaccine application; Lilly buys Orna for up to US$ 2.4 billion

    FDA refuses to review Moderna’s mRNA-based flu vaccine application; Lilly buys Orna for up to US$ 2.4 billion

    The US Food and Drug Administration (FDA) has said it will not review Moderna’s application for its experimental influenz...

    Impressions : 1838

    J&J’s 2026 sales may cross US$ 100 bn; FDA delays fast-track reviews of drugs under Trump’s voucher program

    J&J’s 2026 sales may cross US$ 100 bn; FDA delays fast-track reviews of drugs under Trump’s voucher program

    In 2022, Pfizer had crossed US$ 100 billion in revenue owing to its Covid products. While that was a one-off, Johnson & Johnson...

    Impressions : 1764

    Merck to buy Cidara for US$ 9.2 bn to strengthen infectious disease portfolio; J&J to acquire Halda for US$ 3.05 bn

    Merck to buy Cidara for US$ 9.2 bn to strengthen infectious disease portfolio; J&J to acquire Halda for US$ 3.05 bn

    In this week’s Phispers, Merck struck a US$ 9.2 billion deal to acquire Cidara Therapeutics to strengthen its infectious-...

    Impressions : 1241

    Innovent, Takeda ink up to US$ 11.4 bn oncology deal; FDA clears Novo’s Rybelsus to reduce heart risk in diabetics

    Innovent, Takeda ink up to US$ 11.4 bn oncology deal; FDA clears Novo’s Rybelsus to reduce heart risk in diabetics

    In this week’s Phispers, China’s Innovent Biologics signed one of the largest cross-border biotech deals in Asia. U...

    Impressions : 1561

    Pfizer buys Metsera for up to US$ 7.3 bn, Roche acquires 89bio; FDA okays injectable version of Merck’s Keytruda

    Pfizer buys Metsera for up to US$ 7.3 bn, Roche acquires 89bio; FDA okays injectable version of Merck’s Keytruda

    In this week’s Phispers, Pfizer announced the acquisition of New York-based biotech Metsera for up to US$ 7.3 billion, ma...

    Impressions : 1810

    FDA grants accelerated nod to Boehringer’s lung cancer med; reinstates ousted CBER chief Vinay Prasad

    FDA grants accelerated nod to Boehringer’s lung cancer med; reinstates ousted CBER chief Vinay Prasad

    The US Food and Drug Administration (FDA) has granted an accelerated approval to Boehringer Ingelheim’s Hernexeos (zonger...

    Impressions : 1869

    Merck buys Verona for US$ 10 bn, gains its COPD med; Summit, Astra reportedly in talks for US$ 15 bn cancer drug deal

    Merck buys Verona for US$ 10 bn, gains its COPD med; Summit, Astra reportedly in talks for US$ 15 bn cancer drug deal

    The world of pharmaceuticals continued to witness large deals. Merck announced a US$ 10 billion acquisition of Verona Pharma, g...

    Impressions : 995

    AbbVie enters obesity race with US$ 2.23 bn deal with Denmark’s Gubra; Roche’s TNKase approved for treating strokes

    AbbVie enters obesity race with US$ 2.23 bn deal with Denmark’s Gubra; Roche’s TNKase approved for treating strokes

    AbbVie has forayed into the obesity treatment market with a US$ 2.23 billion licensing deal with Denmark’s Gubra for its ...

    Impressions : 1184

    FDA approves Ozempic to treat CKD in diabetes patients; AbbVie, Neomorph ink US$ 1.64 bn deal for molecular glue degraders

    FDA approves Ozempic to treat CKD in diabetes patients; AbbVie, Neomorph ink US$ 1.64 bn deal for molecular glue degraders

    Novo Nordisk’s Ozempic became the first glucagon-like peptide 1 (GLP-1) drug to receive the US Food and Drug Administrati...

    Impressions : 1326

    J&J buys Intra-Cellular for US$ 14.6 bn; FTC exposes PBMs’ US$ 7.3 bn drug price markup scheme

    J&J buys Intra-Cellular for US$ 14.6 bn; FTC exposes PBMs’ US$ 7.3 bn drug price markup scheme

    The week saw the J.P. Morgan Healthcare Conference kick off with a flurry of deals. In all, deals worth over US$ 19.3 billion ...

    Impressions : 1724

    Lilly’s Zepbound becomes first FDA-approved therapy for sleep apnea; Novo wins nod for daily hemophilia shot

    Lilly’s Zepbound becomes first FDA-approved therapy for sleep apnea; Novo wins nod for daily hemophilia shot

    This week’s Phispers is a double bill with news from the last two weeks. Through much of December, the US Food and Drug A...

    Impressions : 1462

    Merck inks US$ 3.3 bn cancer deal with LaNova; vaccine makers’ stocks tumble after Trump picks RFK Jr to head HHS

    Merck inks US$ 3.3 bn cancer deal with LaNova; vaccine makers’ stocks tumble after Trump picks RFK Jr to head HHS

    This week, Merck struck a strategic US$ 3.3 billion deal with LaNova Medicines for a promising cancer drug, and also demonstr...

    Impressions : 1964

    Astra invests US$ 2 bn in US R&D; key AbbVie asset from US$ 8.7 bn Cerevel buy flunks phase 2 trials

    Astra invests US$ 2 bn in US R&D; key AbbVie asset from US$ 8.7 bn Cerevel buy flunks phase 2 trials

    This week’s Phispers is packed with news about deals. First, AstraZeneca announced a US$ 2 billion investment in the...

    Impressions : 1089

    Sanofi gets two bids valuing its consumer unit at US$ 17 bn; Pfizer pulls SCD drug from market

    Sanofi gets two bids valuing its consumer unit at US$ 17 bn; Pfizer pulls SCD drug from market

    In news this week, Sanofi is considering the sale of its consumer health unit and has received binding bids valuing the divisi...

    Impressions : 1518

    GSK’s COPD, long-acting asthma drugs score late-stage wins; Novo’s weight-loss drug Saxenda found to be safe in kids

    GSK’s COPD, long-acting asthma drugs score late-stage wins; Novo’s weight-loss drug Saxenda found to be safe in kids

    GSK scored a significant late-stage win with its asthma drug Nucala in treating chronic obstructive pulmonary disease (COPD). I...

    Impressions : 1182

    FDA approves Emergent’s smallpox vaccine for mpox; Lilly inks up to US$ 1 bn deal with Haya to target obesity

    FDA approves Emergent’s smallpox vaccine for mpox; Lilly inks up to US$ 1 bn deal with Haya to target obesity

    This week saw the US Food and Drug Administration (FDA) respond to the global monkeypox (mpox) public health emergency by expan...

    Impressions : 1316

    FDA rejects first MDMA therapy to treat PTSD; Merck, Curon ink up to US$ 1.3 bn deal for next-gen bispecific antibody

    FDA rejects first MDMA therapy to treat PTSD; Merck, Curon ink up to US$ 1.3 bn deal for next-gen bispecific antibody

    The US Food and Drug Administration (FDA) has declined to approve an MDMA-assisted therapy from Lykos Therapeutics to treat pos...

    Impressions : 1818

    FDA approves first ever T-cell receptor gene therapy from Adaptimmune, Servier’s brain tumor pill

    FDA approves first ever T-cell receptor gene therapy from Adaptimmune, Servier’s brain tumor pill

    This week, Adaptimmune clinched gold when it secured the first-ever US Food and Drug Administration (FDA) approval for a T-cell...

    Impressions : 1171

    US Senate passes bipartisan bill to cut pharma patent abuses; Ipsen inks another ADC deal

    US Senate passes bipartisan bill to cut pharma patent abuses; Ipsen inks another ADC deal

    This week, a bill heralded as “critical” to help “end anti-competitive practices” was passed by the US ...

    Impressions : 1505

    Lilly to acquire IBD drug developer Morphic for US$ 3.2 bn; Pfizer’s R&D chief to step down

    Lilly to acquire IBD drug developer Morphic for US$ 3.2 bn; Pfizer’s R&D chief to step down

    This week saw Eli Lilly strike yet another deal as it announced the acquisition of Morphic Holding for about US$ 3.2 billion, t...

    Impressions : 1365

    France draws US$ 2.25 bn investment from Big Pharma; Sanofi strikes US$ 1.2 bn deal with Novavax

    France draws US$ 2.25 bn investment from Big Pharma; Sanofi strikes US$ 1.2 bn deal with Novavax

    In this week’s news, France attracted investments from pharma majors such as Sanofi, Pfizer, AstraZeneca and GSK during t...

    Impressions : 1168

    ImmunityBio bags maiden FDA nod for bladder cancer; Ipsen, Skyhawk partner to develop neurological therapies

    ImmunityBio bags maiden FDA nod for bladder cancer; Ipsen, Skyhawk partner to develop neurological therapies

    This week’s Phispers comes packed with news about drug approvals by the US Food and Drug Administration (FDA). The agency...

    Impressions : 1230

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.